GRAIL, Inc. $GRAL Shares Purchased by Allianz Asset Management GmbH

Allianz Asset Management GmbH lifted its stake in shares of GRAIL, Inc. (NASDAQ:GRAL) by 145.9% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 294,835 shares of the company’s stock after purchasing an additional 174,959 shares during the period. Allianz Asset Management GmbH owned approximately 0.82% of GRAIL worth $17,434,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Atlantic Union Bankshares Corp acquired a new position in shares of GRAIL in the third quarter worth about $64,000. Jones Financial Companies Lllp boosted its stake in GRAIL by 200.8% in the 3rd quarter. Jones Financial Companies Lllp now owns 4,509 shares of the company’s stock worth $267,000 after purchasing an additional 3,010 shares during the period. Mutual Advisors LLC purchased a new position in GRAIL during the 3rd quarter worth approximately $1,749,000. Trifecta Capital Advisors LLC grew its position in GRAIL by 89.9% during the 3rd quarter. Trifecta Capital Advisors LLC now owns 21,650 shares of the company’s stock worth $1,280,000 after purchasing an additional 10,250 shares in the last quarter. Finally, Cypress Capital Management LLC WY raised its stake in GRAIL by 64.3% during the 3rd quarter. Cypress Capital Management LLC WY now owns 2,300 shares of the company’s stock valued at $136,000 after purchasing an additional 900 shares during the period.

GRAIL Stock Performance

GRAL opened at $100.07 on Friday. The company has a market cap of $3.90 billion, a PE ratio of -8.60 and a beta of 4.52. The stock has a 50-day moving average of $97.26 and a 200-day moving average of $72.12. GRAIL, Inc. has a 52-week low of $20.44 and a 52-week high of $118.84.

GRAIL (NASDAQ:GRAL) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($2.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.40) by $0.94. The company had revenue of $36.19 million during the quarter, compared to analysts’ expectations of $33.83 million. GRAIL had a negative net margin of 286.43% and a negative return on equity of 15.69%. On average, research analysts predict that GRAIL, Inc. will post -15.15 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on GRAL shares. Guggenheim lifted their target price on GRAIL from $100.00 to $130.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Weiss Ratings restated a “sell (d-)” rating on shares of GRAIL in a report on Thursday, January 22nd. Canaccord Genuity Group boosted their price objective on shares of GRAIL from $85.00 to $105.00 and gave the company a “buy” rating in a research report on Monday, November 17th. Finally, Morgan Stanley increased their target price on shares of GRAIL from $85.00 to $110.00 and gave the stock an “equal weight” rating in a research report on Monday, December 1st. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, GRAIL presently has an average rating of “Hold” and a consensus target price of $105.00.

GRAIL Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.